Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Carboplatin/Paclitaxel, and Radiation in Stage III NSCLC
NCT00578149Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2006
- Primary completion
- Aug 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Time to Progression. Started May 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00578149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00578149.